- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04071379
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B
January 13, 2022 updated by: PT Bio Farma
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B at Birth Dose (Using Different Source of Hepatitis B), in Indonesian Infants
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) with Pentabio® vaccine Primed with Recombinant Hepatitis B
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) with Pentabio® vaccine Primed with Recombinant Hepatitis B at Birth dose (using different source of Hepatitis B), in Indonesian Infants
Study Type
Interventional
Enrollment (Actual)
220
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
West Java
-
Bandung, West Java, Indonesia
- Garuda Primary Health Centre
-
Bandung, West Java, Indonesia
- Ibrahim Adjie Primary Health Centre
-
Bandung, West Java, Indonesia
- Puter Primary Health Care
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second to 3 days (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy, full term, newborns infants.
- Infant born after 37-42 weeks of pregnancy.
- Infant weighing 2500 gram or more at birth.
- Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form.
- Parents will commit themselves to comply with the indications of the investigator and with the schedule of the trial.
Exclusion Criteria:
- Child concomitantly enrolled or scheduled to be enrolled in another trial.
- Mother with HBsAg positive.
- Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature >37.5C on Day 0).
- Suspected of allergy to any component of the vaccines (e.g. formaldehyde).
- Suspected of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.
- Newborn suspected of congenital or acquired immunodeficiency (including HIV infection).
- Received or plans to receive any treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (> 2 weeks)).
- Received other vaccination with the exception of BCG and poliomyelitis.
- Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HepB + Penta batch 1
Recombinant Hepatitis B + DTP-HB-Hib batch 1
|
1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
Other Names:
|
Active Comparator: Hep B + Pentabio (registered)
Recombinant Hepatitis B + Pentabio (registered)
|
1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) with new Hepatitis B bulk
Time Frame: 28 days after immunization
|
Percentage of infants with anti-diphtheria titer and anti-tetanus titer > 0.01 IU/ml, anti HbsAg titer > 10 mIU/ml, and anti PRP-T titer > 0.15 ug/ml 28 days after the last injection of DTP/HB/Hib with different source of Hepatitis B bulk vaccine group.
|
28 days after immunization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Describes antibody response to diphtheria toxoid, tetanus toxoid in both group with the evaluation criteria
Time Frame: 28 days after immunization
|
Serological response to diphtheria toxoid, tetanus toxoid: GMT, percentage of infants with titer > 0.01 IU/ml, > 0.1 IU/ml percentage of infants with increasing antibody titer > 4 times and/or percentage of infants with transition of seronegative to seropositive
|
28 days after immunization
|
Serological response to the pertussis component (agglutinins)
Time Frame: 28 days after immunization
|
Serological response to the pertussis component (agglutinins): GMT, percentage of infants with titer > 40, > 80, > 160 and > 320 (1/dil.),
percentage of infants with increasing antibody titer > 4 times
|
28 days after immunization
|
Geometric mean of anti-HbsAg
Time Frame: 28 days after immunization
|
Geometric mean of anti-HbsAg, percentage of infants with titer > 10mIU/ml, percentage of infants with increasing antibody titer > 4 times and/ or percentage of infants with transition of seronegative to seropositive
|
28 days after immunization
|
Serological response to Hib/PRP
Time Frame: 28 days after immunization
|
Serological response to Hib/PRP: GMT, percentage of infants with titer >1 ug /ml ; > 0.15 ug /ml percentage of infants with increasing antibody titer > 4 times and/or percentage of infants with transition of seronegative to seropositive
|
28 days after immunization
|
Seroconversion
Time Frame: 28 days after immunization
|
Comparison of GMT, seroprotection, percentage of subjects with increasing antibody titer > 4 times and/ or percentage of subjects with transition of seronegative to seropositive following primary series of investigational product compare to control.
|
28 days after immunization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eddy Fadliyana, Hasan Sadikin General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 13, 2020
Primary Completion (Actual)
April 6, 2021
Study Completion (Actual)
December 16, 2021
Study Registration Dates
First Submitted
August 26, 2019
First Submitted That Met QC Criteria
August 26, 2019
First Posted (Actual)
August 28, 2019
Study Record Updates
Last Update Posted (Actual)
January 18, 2022
Last Update Submitted That Met QC Criteria
January 13, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Penta BS19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety
-
Anne Estrup OlesenAalborg University; University College of Northern Denmark; Aalborg KommuneRecruitingPatient Safety | Medication SafetyDenmark
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentTerminatedPatient Empowerment | Patient Safety | Medication SafetyNetherlands
-
The University of Texas Health Science Center,...CompletedMedical Education | Patient Safety | Educational Safety Curriculum | Surgical Resident
-
Korea Otsuka Pharmaceutical Co., Ltd.Recruiting
-
MicuRxWorldwide Clinical TrialsCompleted
-
Provention Bio, Inc.Completed
-
Chris Lascola, MDDuke UniversityWithdrawn
-
Algenis SpACovanceCompleted
-
Alan RichardsonQuotient ClinicalTerminated
-
Good Food Practice, SwedenBioGaia ABCompleted
Clinical Trials on Recombinant Hepatitis B + DTP-HB-Hib
-
PT Bio FarmaHasan Sadikin General HospitalNot yet recruitingDiphtheria Vaccine Adverse Reaction | Tetanus Vaccine Adverse Reaction | Pertussis Vaccine Adverse Reaction | Haemophilus Influenzae Type B Vaccine Adverse Reaction | Hepatitis B Vaccine Adverse ReactionIndonesia
-
PT Bio FarmaCompleted
-
PT Bio FarmaCompleted
-
Serum Institute of India Pvt. Ltd.PATHTerminatedImmune Response to DTP-HB-Hib VaccineIndia
-
Rockefeller UniversityCompletedHepatitis BUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Children's National Research InstitutePfizerCompletedImmunization | Hepatitis B Vaccine | Poliovirus Vaccine, Inactivated | DTaP Vaccine | MMR Vaccine | HIB-vaccine | Chickenpox Vaccine | Pneumococcal Polysaccharide Vaccine
-
PT Bio FarmaCompleted
-
PT Bio FarmaCompleted
-
Jiangsu Province Centers for Disease Control and...CompletedHepadnaviridae Infections | DNA Virus Infections | Virus DiseaseChina